| |
27th of April 2018 |
| Time | Title & Speaker | Duration |
| 11:30 | Registration
| |
| 12:00 – 12:15 | Welcome and Introduction
| 15min |
| 12:15 – 12:45 | The International Quality Network for Pathology (IQN-Path) update
John Garratt, Canadian Immunohistochemistry Quality Control (cIQc), Vancouver Canada | 30min |
| 12:50 – 13:20 | A National Population-based Approach to Laboratory Quality Improvement
Niall Swan, St Vincent’s University Hospital and UCD School of Medicine, Dublin, Ireland | 30min |
| 13:25 – 13:55 | RCPAQAP Update and the Challenges of implementing PD-L1 EQA
Julia Pagliuso, RCPAQAP, St Leonards NSW, Australia | 30min |
| 14:00 – 14:30 | Review of results of ALK EQA over 2 years
Zenobia Haffajee, RCPAQAP, St Leonards NSW, Australia | 30min |
| 14:30 – 15:00 | Coffee Break
| 30min |
| 15:00 – 15:30 | TMA based external quality assurance, the cIQc programme.
John Garratt, Canadian Immunohistochemistry Quality Control (cIQc), Vancouver Canada | 30min |
| 15:35 – 16:05 | Biobanking and quality assurance management relevant to IHC: a North American perspective
Christopher Andry, Boston University Medical Center, Boston, USA | 30min |
| 16:10 – 16:40 | Digital Immunohistochemistry and Personalized Medicine in Norway.
Emiel Janssen, Stavanger University Hospital, Norway | 30min |
| 16:45 – 17:15 | An update on Australian medical laboratory accreditation requirements.
Gillian Treloar, NATA (National Association of Testing Authorities, Australia), Melbourne, Australia | 30min |
| 18:30 – 20:30 | Cocktail Party – sponsored by Metagene
| 2hrs |
| |
28th of April 2018 |
| Time | Title & Speaker | Duration |
| 8:00 | Registration
| |
| 8:30 – 9:10 | A Window Onto the Molecular Biology of Tumors
Allen Gown, PhenoPath and Fred Hutchinson Cancer Research Center, Seattle, USA: Next Generation Immunohistochemistry | 40min |
| 9:15 – 9:45 | The role of p16 immunohistochemistry in head and neck tumor diagnosis and management
Jane Dahlstrom, ACT Pathology, Canberra University Hospital and Australian National University Medical School, Australia | 30min |
| 9:50 – 10:20 | Doing it right – Mismatch repair (MMR) for determining eligibility for immuno-modulator therapy
John Garratt, Canadian Immunohistochemistry Quality Control (cIQc), Vancouver Canada | 30min |
| 10:25 – 11:00 | Coffee Break
| 35min |
| 11:00 – 11:30 | Standardization and optimization of antibodies in gastrointestinal cancer diagnosis
Nathan Acott, PathWest Laboratory Medicine, Nedlands WA, Australia | 30min |
| 11:35 – 12:05 | Standardization and optimization of B-Raf v600e
John Garratt, Canadian Immunohistochemistry Quality Control (cIQc), Vancouver Canada | 30min |
| 12:10 – 12:40 | Tests Predictive of Response to PD-L1 and PD-1 Targeted Therapies
Allen Gown PhenoPath and Fred Hutchinson Cancer Research Center, Seattle, USA | 30min |
| 12:45 – 13:30 | Lunch
| 45min |
| 13:30 – 14:00 | From the Newfoundland scandal to present day – Optimization of breast biomarker testing in Canada
John Garratt, Canadian Immunohistochemistry Quality Control (cIQc), Vancouver Canada | 30min |
| 14:05 – 14:35 | The role of IHC in breast cancer diagnosis and optimization of patient management
Emiel Janssen, Stavanger University Hospital, Norway: | 30min |
| 14:40 – 15:10 | Standardization and optimization of antibodies in breast cancer diagnosis
Nathan Acott, PathWest Laboratory Medicine, Nedlands WA, Australia | 30min |
| 15:10 – 15:40 | Coffee Break
| 30min |
| 15:45 – 16:15 | Immunohistochemistry in Endocrine Tumours, a Diagnostic and Theranostic Role
Niall Swan, St Vincent’s Univesity Hospital and UCD School of Medicine, Dublin, Ireland | 30min |
| 16:20 – 16:50 | Standardization and optimization in lung cancer diagnosis
John Garratt, Canadian Immunohistochemistry Quality Control (cIQc), Vancouver Canada | 30min |
| 16:55 – 17:25 | Standardization and optimization of antibodies in lung cancer diagnosis
Nathan Acott, PathWest Laboratory Medicine, Nedlands WA, Australia | 30min |
| 19:30 – | Drinks and Gala Dinner
| – |
| |
29th of April 2018 |
| Time | Title & Speaker | Duration |
| 8:00 | Registration
| |
| 8:30 – 9:00 | The role of Immunohistochemistry in the diagnosis and management of unknown soft tissue tumours.
John Slavin, St Vincent’s Univesity Hospital, VIC Melbourne, Australia | 30min |
| 9:05 – 9:35 | Rationale and Cost-Effective Use of Antibody Panels in Immunohistochemistry: Allen Gown, PhenoPath Seattle
Allen Gown, PhenoPath and Fred Hutchinson Cancer Research Center, Seattle, USA | 30min |
| 9:40 – 10:10 | Digital and quantitative immunohistochemistry in Bladder cancer
Emiel Janssen, Stavanger University Hospital, Norway | 30min |
| 10:15 – 10:45 | Coffee Break
| 30min |
| 10:50 – 11:20 | Specimen quality and pre-analytic variables
Christopher Andry, Boston University Medical Center, Boston, USA | 30min |
| 11:25 – 11:55 | The crispy brown stain in IHC – can it be misleading; Errors made and lessons learnt
Beena Kumar, Monash Medical Centre, Melbourne, VIC, Australia | 30min |
| 12:00 – 12:30 | Introducing iCAPCs (Immunohistochemistry Critical Assay Performance Controls )
John Garratt, Canadian Immunohistochemistry Quality Control (cIQc), Vancouver Canada | 30min |
| 12:35 – 13:05 | Immunohistochemistry- Headaches Heartbreaks and Heroics
David Gan, QML Pathology Brisbane and RCPASQAP St Leonards NSW, Australia | 30min |
